EGFR and non-small cell lung carcinoma: In the study named KN046-201 (NCT03838848), a total of 26 advanced NSCLC patients with EGFR sensitivity mutation who had failed EGFR-TKI(s) and without platinum-based chemotherapy were enrolled and were given KN046 in combination with pemetrexed and carboplatin as a second-line treatment (95).